Fungal Infections of Implantation (Chromoblastomycosis, Mycetoma, Entomophthoramycosis, and Lacaziosis)

  • Flavio Queiroz-TellesEmail author
  • Daniel Wagner de C. L. Santos
  • Conceição de Maria Pedrozo S. Azevedo
Part of the Infectious Disease book series (ID)


Implantation mycoses include a heterogeneous group of fungal diseases that develop at the site of transcutaneous trauma. They are also known as “subcutaneous mycoses,” but this term seems to be imprecise because some of implantation mycoses may also involve muscles, fascia, cartilage, and bones, beyond the skin and the subcutaneous tissues. These diseases are a frequent health problem in Latin American countries and other tropical and subtropical areas of the world. Although these infections rarely cause disseminated or invasive disease, they have an important impact on public health, may be difficult to control, and often recur.The implantation mycoses covered in this chapter include chromoblastomycoses, eumycetoma, lacaziosis, and entomophthoramycoses.


Subcutaneous mycoses Chromoblastomycosis Chromomycosis Eumycetoma Mycetoma Maduromycosis Lacaziosis Lobomycosis Lobo’s disease Entomophthoramycosis Subcutaneous zygomycosis Subcutaneous mucormycosis 


  1. 1.
    Errol Reiss H, Shadomy HJ, Lyon M. Mycoses of implantation: fundamental medical mycology. Hoboken: Wiley-Blackwell; 2012. 475p.Google Scholar
  2. 2.
    Queiroz-Telles F, Nucci M, Colombo AL, et al. Mycoses of implantation in Latin America: an overview of epidemiology, clinical manifestations, diagnosis and treatment. Med Mycol. 2011;49:225–36.CrossRefPubMedGoogle Scholar
  3. 3.
    Bayles MA. Chromomycosis. In: Hay RJ, Herausgeber, Baillière’s clinical tropical medicine and communicable diseases. Tropical fungal infections. London: WB Saunders; 1986. p. 45–70.Google Scholar
  4. 4.
    La Hoz RM Baddley JW. Subcutaneous fungal infections. Curr Infect Dis Rep. 2012; published online 19 July 2012.Google Scholar
  5. 5.
    Lupi O, Tyring SK, McGinnis MR. Tropical dermatology: fungal tropical diseases. J Am Acad Dermatol. 2005;53:931–51.CrossRefPubMedGoogle Scholar
  6. 6.
    Pang KR, Wu JJ, Huang DB, Tyring SK. Subcutaneous fungal infections. Dermatol Ther. 2004;17:523–31.CrossRefPubMedGoogle Scholar
  7. 7.
    Queiroz-Telles F, Mc Ginnis MR, Salkin I, Graybill JR. Subcutaneous mycoses. Infect Dis Clin North Am. 2003;17:59–85.CrossRefPubMedGoogle Scholar
  8. 8.
    Garnica M, Nucci M, Queiroz-Telles F. Difficult mycoses of the skin: advances in the epidemiology and management of eumycetoma, phaeohyphomycosis and chromoblastomycosis. Curr Opin Infect Dis. 2009;22:559–63.CrossRefPubMedGoogle Scholar
  9. 9.
    Rippon JW. Chromoblastomycosis and related dermal infections caused by dematiaceous fungi. In: Rippon JW, editor. Medical mycology. The pathogenic fungi and the pathogenic actinomycetes. 2 edn. Philadelphia: WB Saunders; 1982. p. 249–76.Google Scholar
  10. 10.
    Esterre P, Andriantsimahavandy A, et al. Forty years of chromoblastomycosis in Madagascar: a review. Am J Trop Med Hyg. 1996;55:45–7.PubMedGoogle Scholar
  11. 11.
    Silva JP, de Souza W, Rozental S. Chromoblastomycosis: a retrospective study of 325 cases on Amazonic Region (Brazil). Mycopathologia. 1998;143:171–5.CrossRefPubMedGoogle Scholar
  12. 12.
    Bonifaz A, Carrasco-Gerard E, Saul A. Chromoblastomycosis: clinical and mycologic experience of 51 cases. Mycoses 2001;44:1–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Queiroz-Telles F, Esterre P, Perez-Blanco M, et al. Chromoblastomycosis: an overview of clinical manifestations, diagnosis and treatment. Med Mycol. 2009;47:3–15.CrossRefPubMedGoogle Scholar
  14. 14.
    Rudolph M. Über die brasilianische “Figueira” Vorläufige Mitteilung. Archiev Schiffs und Tropen-Hyg. 1914;18:498–9.Google Scholar
  15. 15.
    Castro RM, Castro LGM. On the priority of description chromomycosis. Mykosen. 1987;30:397–403.CrossRefPubMedGoogle Scholar
  16. 16.
    Esterre P, Queiroz-Telles F. Management of chromoblastomycosis: novel perspectives. Curr Opin Infect Dis. 2006;19:148–52.CrossRefPubMedGoogle Scholar
  17. 17.
    Fader RC, McGinnis MR. Infections caused by dematiaceous fungi: chromoblastomycosis and phaeohyphomycosis. Infect Dis Clin North Am. 1988;2(4):925–38.PubMedGoogle Scholar
  18. 18.
    Revankar SG, Sutton DA. Melanized fungi in human disease. Clin Microbiol Rev. 2010;23:884–928.CrossRefPubMedCentralPubMedGoogle Scholar
  19. 19.
    Borelli D. Acrotheca aquaspersa nova, new species agent of chromomycosis. Acta Cient Venez. 1972;23:193–6.PubMedGoogle Scholar
  20. 20.
    Barba-Gomez JF, Mayorga J, McGinnis MR, Gonzalez-Mendoza A. Chromoblastomycosis caused by Exophiala spinifera. J Am Acad Dermatol. 1992;26:367–70.CrossRefPubMedGoogle Scholar
  21. 21.
    de Hoog GS Attili-Angelis D Vicente VA Van Den Ende AH Queiroz-Telles F. Molecular ecology and pathogenic potential of Fonsecaea species. Med Mycol. 2004;42:405–16.CrossRefPubMedGoogle Scholar
  22. 22.
    Najafzadeh MJ, Gueidan C, Badali H, van den Ende AH, Xi L, de Hoog GS. Genetic diversity and species delimitation in the opportunistic genus Fonsecaea. Med Mycol. 2009;47:17–25.CrossRefPubMedGoogle Scholar
  23. 23.
    Matsumoto T, Matsuda T, McGinnis MR, Ajello L. Clinical and mycological spectra of Wangiella dermatitidis infections. Mycoses. 1993;36:145–55.CrossRefPubMedGoogle Scholar
  24. 24.
    McGinnis MR. Chromoblastomycosis and phaeohyphomycosis: new concepts, diagnosis, and mycology. J Am Acad Dermatol. 1983;8:1–16.CrossRefPubMedGoogle Scholar
  25. 25.
    de Hoog GS, Nishikaku AS, Fernandez-Zeppenfeldt G, et al. Molecular analysis and pathogenicity of the Cladophialophora carrionii complex, with the description of a novel species. Stud Mycol. 2007;58:219–34.CrossRefPubMedCentralPubMedGoogle Scholar
  26. 26.
    Al-Doory Y. Chromomycosis. In: Di Salvo, AF editor. Occupational mycoses. Philadelphia: Lea & Febiger; 1983. p. 95–121.Google Scholar
  27. 27.
    Vicente AP, Attili DA, Queiroz-Telles F, et al. Isolation of Herpotrichiellacious fungi from the environment. Braz J Microbiol. 2001;32:47–51.CrossRefGoogle Scholar
  28. 28.
    Queiroz-Telles F, Santos, DWCL. Chromoblastomycosis in the clinical practice. Curr Fungal Infect Rep. doi:10.1007/s12281-012-0116-8.Google Scholar
  29. 29.
    Minotto R, Bernardi CDV, Mallmann LF, Edelweiss MIA, Scroferneker ML. Chromoblastomycosis: a review of 100 cases in the state of Rio Grande do Sul. J Am Acad Dermatol. 2001;44:585–92.CrossRefPubMedGoogle Scholar
  30. 30.
    Perez-Blanco M, Hernández Valles R, Garcia-Humbria L, Yegres F. Chromoblastomycosis in children and adolescents in the endemic area of the falcon state, Venezuela. Med Mycol. 2006;44:467–71.CrossRefPubMedGoogle Scholar
  31. 31.
    Tschen JA, Knox JM, McGavran MH, Duncan C. Chromomycosis. Association of fungal elements and wood splinters Arch Dermatol 1974;120:107–8.CrossRefGoogle Scholar
  32. 32.
    Gezuele E, Mackinnon JE, Conti-Diaz IA. The frequent isolation of Phialophora verrucosa and Phialophora pedrosoi from natural sources. Sabouraudia. 1972;10:266–73.CrossRefPubMedGoogle Scholar
  33. 33.
    Tsuneto LT, Arce-Gomez B, Petzl-Erler ML, Queiroz-Telles F. HLA-A29 and genetic susceptibility to chromoblastomycosis. J Med Vet Mycol. 1989;27:181–5.CrossRefPubMedGoogle Scholar
  34. 34.
    Castro Lima Santos D Pedroso e Silva Cde M Almeida SR. Cytokines and lymphocyte proliferation in patients with different clinical forms of chromoblastomycosis. Microbes Infect. 2005;7:708–13.CrossRefGoogle Scholar
  35. 35.
    Palmeira VF, Kneipp LF, Alviano CS, dos Santos AL. Phospholipase and esterase production by clinical strains of Fonsecaea pedrosoi and their interactions with epithelial cells. Mycopathologia 2010;170:31–7.CrossRefPubMedGoogle Scholar
  36. 36.
    Carrion AL. Chromoblastomycosis. Ann NY Acad Sci. 1950;50:1255–82.CrossRefPubMedGoogle Scholar
  37. 37.
    Esterre P, Pecarrère JL, Raharisolo C, Huerre M. Squamous cell carcinoma arising from chromomycosis. Report of two cases. Ann Pathol. 1999;19(6):516–20.PubMedGoogle Scholar
  38. 38.
    Jamil A, Lee YY, Thevarajah S. Invasive squamous cell carcinoma arising from chromoblastomycosis. Med Mycol. 2012 Jan;50(1):99–102.CrossRefPubMedGoogle Scholar
  39. 39.
    Zaias N, Rebell G. A simple and accurate diagnostic method in chromoblastomycosis. Arch Dermatol. 1973;108:545–6.CrossRefPubMedGoogle Scholar
  40. 40.
    Lee MW, Hsu S, Rosen T. Spores and mycelia in cutaneous chromomycosis. J Am Acad Dermatol. 1998;39:850–2.CrossRefPubMedGoogle Scholar
  41. 41.
    Zaias N. Chromomycosis. J Cutan Pathol. 1978;5:155–64.CrossRefPubMedGoogle Scholar
  42. 42.
    Restrepo A, Gonzalez A, Gomez I, Arango M, de Bedout C. Treatment of chromoblastomycosis with itraconazole. Ann N Y Acad Sci. 1988;544:504–16.CrossRefPubMedGoogle Scholar
  43. 43.
    Queiroz-Telles F, Purim KS, Fillus JN, et al. Itraconazole in the treatment of chromoblastomycosis due to Fonsecaea pedrosoi. Int J Dermatol. 1992;31:805–12.CrossRefPubMedGoogle Scholar
  44. 44.
    Esterre P, Inzan CK, Rtasioharana M, et al. A multicenter trial of terbinafine in patients with chromoblastomycosis: effects on clinical and biological criteria. J Dermatolog Treat. 1998;9:529–34.CrossRefGoogle Scholar
  45. 45.
    Bonifaz A, Saul A, Paredes-Solis V, Araiza J, Fierro-Arias L. Treatment of chromoblastomycosis with terbinafine: experience with four cases. J Dermatolog Treat. 2005;16:47–51.CrossRefPubMedGoogle Scholar
  46. 46.
    Gupta AK, Taborda PR, Sanzovo AD. Alternate week and combination itraconazole and terbinafine therapy for chromoblastomycosis caused by Fonsecaea pedrosoi in Brazil. Med Mycol. 2002;40:529–34.CrossRefPubMedGoogle Scholar
  47. 47.
    Pradinaud R, Bolzinger T. Treatment of chromoblastomycosis. J Am Acad Dermatol. 1991;25:869–70.CrossRefPubMedGoogle Scholar
  48. 48.
    Bolzinger T, Pradinaud R, Sainte-Marie D, Dupont B, Chwetzoff E. Traitement de quatre cas de chromomycose à Fonsecaea pedrosoi par l’association 5-fluorocytosine-itraconazole. Nouv Dermatol. 1991;10:462–6.Google Scholar
  49. 49.
    Antonello VS, Appel da Silva MC, Cambruzzi DA, Santos BR, Queiroz-Telles F. Treatment of severe chromoblastomycosis with itraconazole and 5-flucytosine association. Rev Inst Med Trop São Paulo. 2010;52:329–31.CrossRefPubMedGoogle Scholar
  50. 50.
    Queiroz-Telles F, Santos DW. Challenges in the therapy of chromoblastomycosis. Mycopathologia. 2013;175:477–88.CrossRefPubMedGoogle Scholar
  51. 51.
    Hiruma M, Kawada A, Yoshida M, Kouya M. Hyperthermic treatment of chromomycosis with disposable chemical pocket warmers. Report of a successfully treated case, with a review of the literature. Mycopathologia. 1993;122(2):107–14.CrossRefPubMedGoogle Scholar
  52. 52.
    Azevedo C de M, Marques SG, Resende MA, Gonçalves AG, Santos DV, da Silva RR, de Sousa Mda G, de Almeida SR. The use of glucan as immunostimulant in the treatment of a severe case of chromoblastomycosis. Mycoses. 2008;51(4):341–4.CrossRefGoogle Scholar
  53. 53.
    Calzavara-Pinton PG, Venturini M, Sala R. A comprehensive overview of photodynamic therapy in the treatment of superficial fungal infections of the skin. J Photochem Photobiol B: Biol. 2005;78:1–6.CrossRefGoogle Scholar
  54. 54.
    Lyon JP, Azevedo CMPS, Moreira LM, Lima CG, Resende MA. Photodynamic antifungal therapy against chromoblastomycosis. Mycopathologia. 2011;172:293–7.CrossRefPubMedGoogle Scholar
  55. 55.
    Souza MGT, Belda W Jr., Spina R, et al. Topical application of imiquimod as a treatment for chromoblastomycosis. Clin Infect Dis. 2014;58:1734–37.CrossRefGoogle Scholar
  56. 56.
    Negroni R, Tobon A, Bustamante B, et al. Posaconazole treatment of refractory eumycetoma and chromoblastomycosis. Rev Inst Med Trop Sao Paulo. 2005;47:9–346.CrossRefGoogle Scholar
  57. 57.
    Criado PR, Careta MF, Valente NY, Martins JE, Rivitti EA, Spina R, Belda W Jr. Extensive longstanding chromomycosis due to Fonsecaea pedrosoi: three cases with relevant improvement under voriconazole therapy. J Dermatolog Treat. 2011;22(3):167–74.CrossRefPubMedGoogle Scholar
  58. 58.
    Cortez KJ, Roilides E, Queiroz-Telles F, et al. Infections caused by Scedosporium. Clin Microbiol Rev. 2008;157–97.Google Scholar
  59. 59.
    Gill J. Indian naval medical reports—quoted by Ghosh LM, et al., 1950. Madura foot (mycetoma). Indian Med. Gaz. 1842;85:288.Google Scholar
  60. 60.
    Godfrey J. Diseases of the foot not hitherto described. Lancet. 1846;i:593–4.Google Scholar
  61. 61.
    Carter HV. On mycetoma or the fungus disease of India including notes of recent cases and new observations of the structure, etc. of the entophytic growth. Trans Med Physiol Soc Bombay. 1861;7:206–21.Google Scholar
  62. 62.
    Pinoy E. Actinomycoses and mycetomas. Borntragen (Leipzig). 1913;11:929–938.Google Scholar
  63. 63.
    Mahgoub ES, Murray IG. Mycetoma. London: William Heinemann Medical Book; 1973.Google Scholar
  64. 64.
    Ahmed AO, van Leeuwen W, Fahal A, van de Sande W, Verbrugh H, van Belkum A. Mycetoma caused by Madurella mycetomatis: a neglected infectious burden. Lancet Infect Dis. 2004;4:566–74.CrossRefPubMedGoogle Scholar
  65. 65.
    Wendy WJ, van de Sande, Maghoub ES, Fahal Ahmed H, et al. The mycetoma knowledge gap: identification of research priorities. PLoS Negl Trop Dis. 2014;8(3):e2667.CrossRefGoogle Scholar
  66. 66.
    Welsh O, Vera-Cabrera L, Salinas-Carmona MC. Mycetoma. Clin Dermatol. 2007;25(2):195–202.CrossRefPubMedGoogle Scholar
  67. 67.
    Cordeiro F, Bruno C, Reis C. Mycetoma. Am J Trop Med Hyg. 2011;85(5):791.CrossRefPubMedCentralPubMedGoogle Scholar
  68. 68.
    Lichon V, Khachemoune A. Mycetoma: a review. Ann J Clin Dermatol. 2006;7(5):315–21.CrossRefGoogle Scholar
  69. 69.
    Ahmed AA, van de Sande WW, Fahal A, Bakker-Woudenberg I, Verbrugh H, van Belkum A. Management of mycetoma: major challenge in tropical mycoses with limited international recognition. Curr Opin Infect Dis. 2007;20(2):146–51.CrossRefPubMedGoogle Scholar
  70. 70.
    Green WO, Jr., Adams TE. Mycetoma in the United States; a review and report of seven additional cases. Am J Clin Pathol. 1964;42:75–91.PubMedGoogle Scholar
  71. 71.
    McGinnis MR, Fader RC. Mycetoma: a contemporary concept. Infect Dis Clin North Am. 1988;2:939–54.PubMedGoogle Scholar
  72. 72.
    Estrada R, Chávez-López G, Estrada-Chávez G, López-Martínez R, Welsh O. Eumycetoma. Clin Dermatol. 2012;30:389–96.CrossRefPubMedGoogle Scholar
  73. 73.
    Maiti PK, Ray A, Bandyopadhyay S. Epidemiological aspects of mycetoma from a retrospective study of 264 cases in West Bengal. Trop Med Int Health. 2002;7(9):788–91.CrossRefPubMedGoogle Scholar
  74. 74.
    Wendy WJ, van de Sande. Global burden of human mycetoma: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2013;7(11):e2550.CrossRefGoogle Scholar
  75. 75.
    Horre R, Schumacher G, Marklein G, Stratmann H, Wardelmann E, Gilges S, De Hoog GS, Schaal KP. Mycetoma due to Pseudallescheria boydii and co-isolation of Nocardia abscessus in a patient injured in road accident. Med Mycol. 2002;40:525–7.CrossRefPubMedGoogle Scholar
  76. 76.
    Wethered DB, Markey MA, Hay RJ, Mahgoub ES, Gumaa SA. Ultrastructural and immunogenic changes in the formation of mycetoma grains. J Med Vet Mycol. 1987;25:39–46.CrossRefPubMedGoogle Scholar
  77. 77.
    Fahal AH, Sheik HE, Homeida MM, Arabi YE, Mahgoub ES. Ultrasonographic imaging of mycetoma. Br J Surg. 1997;84:1120–2.CrossRefPubMedGoogle Scholar
  78. 78.
    Sharif HS, Clark DC, Aabed MY, Aideyan OA, Mattsson TA, Haddad MC, Ohman SO, Joshi RK, Hasan HA, Haleem A. Mycetoma: comparison of MR imaging with CT. Radiology 1991;178:865–70.CrossRefPubMedGoogle Scholar
  79. 79.
    Ameen M, Arenas R. Emerging therapeutic regimes for the management of mycetomas. Expert Opin Pharmacother. 2008;9(12):2077–85.CrossRefPubMedGoogle Scholar
  80. 80.
    Ameen M. Managing mycetomas. Trop Doct. 2009;39(2):66–8.CrossRefPubMedGoogle Scholar
  81. 81.
    Fahal AH, Rahman IA, El-Hassan AM, Abdel ME, Rahman EI, et al. The safety and efficacy of itraconazole for the treatment of patients with eumycetoma due to Madurella mycetomatis. Trans R Soc Trop Med Hyg. 2011;105:127–32.CrossRefPubMedGoogle Scholar
  82. 82.
    Lobo JO. Um caso de blastomicose produzido por uma espécie nova, encontrada em Recife. Rev Med Pernambuco. 1931;1:763–5.Google Scholar
  83. 83.
    Taborda PR, Taborda VA, McGinnis R. Lacazia loboi gen. nov., com. nov., the etiologic agent of lobomycosis. J Clin Microbiol. 1999:2031–3.Google Scholar
  84. 84.
    Brito AC, Quaresma JAS. Lacaziosis (Jorge Lobo’s disease): review and update. An Bras Dermatol. 2007;82(5):461–74.CrossRefGoogle Scholar
  85. 85.
    Symmers WS. A possible case of Lobo’s disease acquired in Europe from a bottle-nosed dolphin (Tursiops truncatus). Bull Soc Pathol Exot. 1983;77:777–84.Google Scholar
  86. 86.
    Cowen DF. Lobo’s disease in a bottlenose dolphin (Tursiops truncatus) from Matagorda Bay, Texas. J Wildl Dis. 1993;29:488–9.CrossRefGoogle Scholar
  87. 87.
    Lopes PCS, Paula GS, Both VF, Xavier M, Scaramello AC. First case of lobomycosis in a bottlenose dolphin from Southern Brazil. Mar Mamm Sci. 1993;9:329–31.CrossRefGoogle Scholar
  88. 88.
    Bermudez L, Van Bressem MF, Reyes-Jaimes O, et al. Lobomycosis in man and lobomycosis-like disease in bottlenose dolphin, Venezuela. Emerg Infect Dis. 2009;15(8):1301–3.CrossRefPubMedCentralPubMedGoogle Scholar
  89. 89.
    Rotstein DS, Burdett LG, McLellan L, et al. Lobomycosis in offshore bottlenose dolphins (Tursiops truncatus), North Carolina. Emerg Infect Dis. 2009;15(4):588–90.CrossRefPubMedCentralPubMedGoogle Scholar
  90. 90.
    Cáceres S, Rodriguez-Toro G. Lobomicosis de 35 años de evolución. Ver Soc Dermatol. 1991;1:43–5.Google Scholar
  91. 91.
    Miranda MFR, Bittencourt MJS, Costa VS, Brito AC. Transepidermal elimination of parasites in Jorge Lobo’s disease. An Bras Dermatol. 2010;85(1):39–43.CrossRefPubMedGoogle Scholar
  92. 92.
    Paniz-Mondolfi AE, Jaimes OR, Jones LD. Lobomycosis in Venezuela. Int J Dermatol. 2007;46:180–5.CrossRefPubMedGoogle Scholar
  93. 93.
    Bustamante B, Seas C, Salomon M, Bravo F. Lobomycosis successfully treated with Posaconazole. Am J Trop Med Hyg. 2013;88(6):1207–8.CrossRefPubMedCentralPubMedGoogle Scholar
  94. 94.
    Paltauf AP. Mycosis mucorina. Virchow’s Archiv fur Pathologische Anatomie und Physiologie und fur klinische Medicin. 1885;102:543–64.Google Scholar
  95. 95.
    Kwon-Chung KJ, Bennett JE. Medical mycology. Philadelphia: Lea & Febiger; 1992. S. 3–34.Google Scholar
  96. 96.
    Kwon-Chung KJ. Taxonomy of fungi causing mucormycosis and entomophthoramycosis (Zygomycosis) and nomenclature of the disease: molecular mycologic perspectives. Clin Infect Dis. 2012;54(Suppl 1):8–15.CrossRefGoogle Scholar
  97. 97.
    Gugnani HC. A review of zygomycosis due to Basidiobolus ranarum. Eur J Epidemiol. 1999;15:923–9.CrossRefPubMedGoogle Scholar
  98. 98.
    Gugnani HC. Entomophthoramycosis due to Conidiobolus. Eur J Epidemiol.1992;8:391–6.CrossRefPubMedGoogle Scholar
  99. 99.
    Ribes JA, Venover-Sams CL, Baker DJ. Clinical microbiology reviews. Zygomycetes Hum Dis. 2000;13(2):236–301.Google Scholar
  100. 100.
    Ahmed AO, JARIE AL, Al-Mohsen I, Suliman AL, et al. Pediatric gastrointestinal basidiobolomycosis. Pediatr Infect Dis J. 2003;22:1007–13.CrossRefGoogle Scholar
  101. 101.
    Kamalam A, Thambia AS. Entomophthtorae basidiobolae successfully treated with KI. Mykoen. 1979;22:82–4.CrossRefGoogle Scholar
  102. 102.
    Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, Sein M, Sein T, Chiou CC, Chu JH, Kontoyiannis DP, Walsh TJ. Epidemiology and outcome of zygomicosis: a review of 929 reported cases. Clin Infect Dis. 2005;41:634–53.CrossRefPubMedGoogle Scholar
  103. 103.
    Vuillecard E, Testa J, Ravisse P, et al. Treatment of three cases of entomophthoramycosis with itraconazole. Bull Soc Fr Mycol Med. 1987;74:403.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  • Flavio Queiroz-Telles
    • 1
    Email author
  • Daniel Wagner de C. L. Santos
    • 2
  • Conceição de Maria Pedrozo S. Azevedo
    • 3
  1. 1.Public Health Department, Hospital de ClinicasFederal University of ParanaCuritibaBrazil
  2. 2.Infectious Diseases, Emilio Ribas Institute of Infectious DiseasesFederal University of São Paulo (UNIFESP)São PauloBrazil
  3. 3.Medicine IFederal University of MaranhãoSão LuisBrazil

Personalised recommendations